1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives.
Endocr Rev 2000;21:168-199.
2. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort.
Ophthalmology 1996;103:958-962.
3. Bartalena L, Marcocci C, Pinchera A. Graves' ophthalmopathy: a preventable disease?
Eur J Endocrinol 2002;146:457-461.
4. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy.
Thyroid 2002;12:855-860.
5. Kim JM, LaBree L, Levin L, Feldon SE. The relation of Graves' ophthalmopathy to circulating thyroid hormone status.
Br J Ophthalmol 2004;88:72-74.
6. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease.
JAMA 1993;269:479-482.
7. Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Arch Intern Med 1990;150:1098-1101.
8. Tallstedt L, Lundell G, Torring O, et al. The Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism.
N Engl J Med 1992;326:1733-1738.
9. Wiersinga WM. Management of Graves' ophthalmopathy.
Nat Clin Pract Endocrinol Metab 2007;3:396-404.
10. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy.
Endocrinol Metab Clin North Am 1987;16:391-407.
11. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
Clin Endocrinol (Oxf) 1997;47:9-14.
12. Classification of eye changes of Graves' disease.
Thyroid 1992;2:235-236.
13. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
J Clin Endocrinol Metab 2005;90:5234-5240.
14. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.
Clin Endocrinol (Oxf) 1993;38:367-372.
15. Tallstedt L, Lundell G, Taube A. Graves' ophthalmopathy and tobacco smoking.
Acta Endocrinol (Copenh) 1993;129:147-150.
16. Winsa B, Mandahl A, Karlsson FA. Graves' disease, endocrine ophthalmopathy and smoking.
Acta Endocrinol (Copenh) 1993;128:156-160.
17. Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review.
Eye (Lond) 2007;21:1135-1145.
18. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption.
Clin Endocrinol (Oxf) 1996;45:477-481.
19. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy.
Ann Intern Med 1998;129:632-635.
20. Solomon DH, Chopra IJ, Chopra U, Smith FJ. Identification of subgroups of euthyroid Graves' ophthalmopathy.
N Engl J Med 1977;296:181-186.
21. Bhatnagar A, Tsirbas A, Douglas RS, et al. Graves' orbitopathy.
Ophthalmology 2007;114:392
22. Petersen IA, Kriss JP, McDougall IR, Donaldson SS. Prognostic factors in the radiotherapy of Graves' ophthalmopathy.
Int J Radiat Oncol Biol Phys 1990;19:259-264.
23. Dayan CM, Dayan MR. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?
Br J Ophthalmol 2007;91:409-410.
24. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.
Thyroid 2008;18:333-346.
25. Soares-Welch CV, Fatourechi V, Bartley GB, et al. Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients.
Am J Ophthalmol 2003;136:433-441.
26. Feldon SE, Muramatsu S, Weiner JM. Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy.
Arch Ophthalmol 1984;102:1469-1472.
27. Mourits MP, Lombardo SH, van der Sluijs FA, et al. Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. An exploratory study.
Orbit 2004;23:161-168.
28. McKeag D, Lane C, Lazarus JH, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.
Br J Ophthalmol 2007;91:455-458.
29. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management.
Endocr Rev 1993;14:747-793.
30. Khoo DH, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Thyroid 1999;9:1175-1180.
31. Gerding MN, vanderMeer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
Clin Endocrinol (Oxf) 2000;52:267-271.
32. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link.
J Clin Endocrinol Metab 2007;92:59-64.